BIOMAT Database Logo BIOMAT Database Logo

Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. 2009

Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Department of Radiation Oncology, University Hospital Center, University of Lausanne, Lausanne, Switzerland.

BACKGROUND The aim of this study was to assess feasibility and efficacy of weekly concomitant boost accelerated postoperative radiation therapy (PORT) with concomitant chemotherapy (CT) in patients with locally advanced head and neck cancer (LAHNC). METHODS Conformal or intensity-modulated 66-Gy RT was performed in 5.5 weeks in 40 patients. Cisplatin was given at days 1, 22, and 43. Median follow-up was 36 months. CONCLUSIONS Grade 3 mucositis, dysphagia, and erythema was observed in ten (25%), nine (23%), and six (13%) patients, respectively. Grade 3 or more anemia was observed in two (6%) patients, and leukopenia in five (13%) patients. No grade 3 or 4 thrombocytopenia was observed. Grade 3 nephrotoxicity was observed in one patient (3%). No treatment-related mortality was observed. Grade 2 or more xerostomia and edema were observed in ten (25%) and one (3%) patient, respectively. Locoregional relapse occurred in eight patients, and seven patients developed distant metastases. Median time to locoregional relapse was 6 months. Three-year overall, disease-free survival, and locoregional control rates were 63%, 62%, and 81%, respectively. Multivariate analysis revealed that the only prognostic factor was nodal status. CONCLUSIONS Reducing overall treatment time using accelerated PORT/CT by weekly concomitant boost (six fractions per week) combined with concomitant cisplatin CT is easily feasible with acceptable morbidity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011182 Postoperative Care The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed) Care, Postoperative,Postoperative Procedures,Procedures, Postoperative,Postoperative Procedure,Procedure, Postoperative
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005260 Female Females

Related Publications

Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer.
February 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
February 2006, Archives of otolaryngology--head & neck surgery,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
July 2006, International journal of radiation oncology, biology, physics,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
October 2004, Acta oto-laryngologica. Supplementum,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
May 2004, The New England journal of medicine,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
June 1993, American journal of clinical oncology,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas.
March 2002, International journal of radiation oncology, biology, physics,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
May 2005, Oral oncology,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck.
October 1999, International journal of radiation oncology, biology, physics,
Berrin Pehlivan, and Francois Luthi, and Oscar Matzinger, and Michael Betz, and Daniela Dragusanu, and Shelley Bulling, and Luc Bron, and Philippe Pasche, and Walter Seelentag, and René O Mirimanoff, and Abderrahim Zouhair, and Mahmut Ozsahin
A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
January 2020, Journal of cancer research and therapeutics,
Copied contents to your clipboard!